Morag Peberdy

Morag Peberdy has specialized in life sciences work for more than 20 years. She has advised numerous biotech and pharmaceutical companies, ranging from start-ups through to big pharma, on drafting and negotiating intellectual property-related agreements. She has particular expertise in IP licenses and strategic drug R&D collaborations.

In her work with innovative multi-national, national, and start-up life sciences companies, Morag regularly:

• provides strategic advice on licensing and partnering
• assists clients to put in place R&D and collaboration agreements, intellectual property pipeline arrangements, joint ventures, option agreements, strategic alliances, and other commercial and IP-related contracts; and
• advises on intellectual property issues arising in corporate transactions, including M&A, IPOs, venture capital investments, royalty monetizations and restructurings

Morag had a background in biological sciences prior to qualifying as a lawyer and sits on the Intellectual Property Advisory Committee of the Bio Industry Association, advising across the spectrum of intellectual property issues impacting life science companies.

Morag’s insight into both contentious and non-contentious IP matters enables her to bring a valuable perspective and breadth of knowledge to strategic intellectual property issues, which is invaluable in assisting clients’ business objectives.

• Member of the UK Bio Industry Association Intellectual Property Advisory Committee for over a decade

Prior to joining Goodwin, Morag was most recently at Covington & Burling LLP.

Recognized as one of the world's leading practitioners in the Lexology Index (formerly Who's Who Legal) Healthcare & Life Sciences 2025 and 2026

Recognized for excellence in the 2024 edition of The Best Lawyers in the United Kingdom

Featured in “IAM Patent 1000 - The World’s Leading Patent Practitioners”

Expert Guides, Patents and Women in Business Law

Recognized as a ‘Notable Practitioner’ by Managing IP UK (2025)